{"id":"dexamethasone","rwe":[],"_fda":{"id":"4250a0b0-e539-57c9-e063-6294a90a4b55","set_id":"01cfaa3e-5e30-18fa-e063-6394a90a084e","openfda":{"nui":["N0000175576","N0000175450"],"unii":["7S5I7G3JQL"],"route":["ORAL"],"rxcui":["197580"],"spl_id":["4250a0b0-e539-57c9-e063-6294a90a4b55"],"brand_name":["Dexamethasone"],"spl_set_id":["01cfaa3e-5e30-18fa-e063-6394a90a084e"],"package_ndc":["80425-0346-1","80425-0346-2","80425-0346-3","80425-0346-4"],"product_ndc":["80425-0346"],"generic_name":["DEXAMETHASONE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["DEXAMETHASONE"],"pharm_class_epc":["Corticosteroid [EPC]"],"pharm_class_moa":["Corticosteroid Hormone Receptor Agonists [MoA]"],"manufacturer_name":["Advanced Rx Pharmacy of Tennessee, LLC"],"application_number":["ANDA201270"],"original_packager_product_ndc":["70868-920"]},"version":"3","warnings":["WARNINGS General Rare instances of anaphylactoid reactions have occurred in patients receiving corticosteroid therapy (see ADVERSE REACTIONS ). Increased dosage of rapidly acting corticosteroids is indicated in patients on corticosteroid therapy subjected to any unusual stress before, during, and after the stressful situation. Cardio-Renal Average and large doses of corticosteroids can cause elevation of blood pressure, sodium and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion. Literature reports suggest an apparent association between use of corticosteroids and left ventricular free wall rupture after a recent myocardial infarction; therefore, therapy with corticosteroids should be used with great caution in these patients. Endocrine Corticosteroids can produce reversible hypothalamic-pituitary adrenal (HPA) axis suppression with the potential for corticosteroid insufficiency after withdrawal of treatment. Adrenocortical insufficiency may result from too rapid withdrawal of corticosteroids and may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. If the patient is receiving steroids already, dosage may have to be increased. Metabolic clearance of corticosteroids is decreased in hypothyroid patients and increased in hyperthyroid patients. Changes in thyroid status of the patient may necessitate adjustment in dosage. Infections General: Patients who are on corticosteroids are more susceptible to infections than are healthy individuals. There may be decreased resistance and inability to localize infection when corticosteroids are used. Infection with any pathogen (viral, bacterial, fungal, protozoan or helminthic) in any location of the body may be associated with the use of corticosteroids alone or in combination with other immunosuppressive agents. These infections may be mild to severe. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases. Corticosteroids may also mask some signs of current infection. Fungal Infections: Corticosteroids may exacerbate systemic fungal infections and therefore should not be used in the presence of such infections unless they are needed to control life-threatening drug reactions. There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure (see PRECAUTIONS : Drug Interactions: Amphotericin B injection and potassium-depleting agents ). Special Pathogens: Latent disease may be activated or there may be an exacerbation of intercurrent infections due to pathogens, including those caused by Amoeba, Candida, Cryptococcus, Mycobacterium, Nocardia, Pneumocystis, Toxoplasma. It is recommended that latent amebiasis or active amebiasis be ruled out before initiating corticosteroid therapy in any patient who has spent time in the tropics or any patient with unexplained diarrhea. Similarly, corticosteroids should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation. In such patients, corticosteroid- induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia. Corticosteroids should not be used in cerebral malaria. Tuberculosis: The use of corticosteroids in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen. If corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis. Vaccination: Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Ki l ed or inactivated vaccines may be administered. However, the response to such vaccines cannot be predicted. Immunization procedures may be undertaken in patients who are receiving corticosteroids as replacement therapy, e.g., for Addison's disease. Viral infections: Chickenpox and measles can have a more serious or even fatal course in pediatric and adult patients on corticosteroids. In pediatric and adult patients who have not had these diseases, particular care should be taken to avoid exposure. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to chickenpox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If exposed to measles, prophylaxis with immune globulin (IG) may be indicated. (See the respective package inserts for VZIG and IG for complete prescribing information.) If chickenpox develops, treatment with antiviral agents should be considered. Ophthalmic: Use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses. The use of oral corticosteroids is not recommended in the treatment of optic neuritis and may lead to an increase in the risk of new episodes. Corticosteroids should not be used in active ocular herpes simplex."],"pregnancy":["Pregnancy Teratogenic Effects: Pregnancy Category C. Corticosteroids have been shown to be teratogenic in many species when given in doses equivalent to the human dose. Animal studies in which corticosteroids have been given to pregnant mice, rats, and rabbits have yielded an increased incidence of cleft palate in the offspring. There are no adequate and well-controlled studies in pregnant women. Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Infants born to mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism."],"description":["DESCRIPTION Dexamethasone Tablets USP, 1.5 mg Each tablet contains: Dexamethasone USP … 1.5 mg. For oral administration."],"precautions":["PRECAUTIONS General The lowest possible dose of corticosteroids should be used to control the condition under treatment. When reduction in dosage is possible, the reduction should be gradual. Since complications of treatment with corticosteroids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used. Kaposi's sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement. Cardio- Renal As sodium retention with resultant edema and potassium loss may occur in patients receiving corticosteroids, these agents should be used with caution in patients with congestive heart failure, hypertension, or renal insufficiency. Endocrine Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently. Gastrointestinal Steroids should be used with caution in active or latent peptic ulcers, diverticulitis, fresh intestinal anastomoses, and nonspecific ulcerative colitis, since they may increase the risk of a perforation. Signs of peritoneal irritation following gastrointestinal perforation in patients receiving corticosteroids may be minimal or absent. There is an enhanced effect due to decreased metabolism of corticosteroids in patients with cirrhosis. Musculoskeletal Corticosteroids decrease bone formation and increase bone resorption both through their effect on calcium regulation (i.e., decreasing absorption and increasing excretion) and inhibition of osteoblast function. This, together with a decrease in the protein matrix of the bone secondary to an increase in protein catabolism, and reduced sex hormone production, may lead to inhibition of bone growth in pediatric patients and the development of osteoporosis at any age. Special consideration should be given to patients at increased risk of osteoporosis (e.g., postmenopausal women) before initiating corticosteroid therapy. Neuro-Psychiatric Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis, they do not show that they affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect. (see DOSAGE AND ADMINISTRATION ). An acute myopathy has been observed with the use of high doses of corticosteroids, most often occurring in patients with disorders of neuromuscular transmission (e.g., myasthenia gravis), or in patients receiving concomitant therapy with neuromuscular blocking drugs (e.g., pancuronium). This acute myopathy is generalized, may involve ocular and respiratory muscles, and may result in quadriparesis. Elevation of creatinine kinase may occur. Clinical improvement or recovery after stopping corticosteroids may require weeks to years. Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids. Ophthalmic lntraocular pressure may become elevated in some individuals. If steroid therapy is continued for more than 6 weeks, intraocular pressure should be monitored. Information for Patients Patients should be warned not to discontinue the use of corticosteroids abruptly or without medical supervision. As prolonged use may cause adrenal insufficiency and make patients dependent on corticosteroids, they should advise any medical attendants that they are taking corticosteroids and they should seek medical advice at once should they develop an acute illness including fever or other signs of infection. Following prolonged therapy, withdrawal of corticosteroids may result in symptoms of the corticosteroid withdrawal syndrome including, myalgia, arthralgia, and malaise. Persons who are on corticosteroids should be warned to avoid exposure to chickenpox or measles. Patients should also be advised that if they are exposed, medical advice should be sought without delay. Drug Interactio ns Aminoglutethimide: Aminoglutethimide may diminish adrenal suppression by corticosteroids. Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure. Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance (see Drug Interactions: Hepatic Enzyme Inducers, Inhibitors and Substrates ). Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy. Anticoagulants, Oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. Antitubercular Drugs: Serum concentrations of isoniazid may be decreased. Cholestyramine: Cholestyramine may increase the clearance of corticosteroids. Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently. Convulsions have been reported with this concurrent use. Dexamethasone Suppression Test (DST): False-negative results in the dexamethasone suppression test (DST) in patients being treated with indomethacin have been reported. Thus, results of the DST should be interpreted with caution in these patients. Digitalis Glycosides: Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia. Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage. Estrogens, including Oral Contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids. Dexamethasone is a moderate inducer of CYP 3A4. Co-adminstration with other drugs that are metabolized by CYP 3A4 (e.g., indinavir, erythromycin) may increase their clearance, resulting in decreased plasma concentration. Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects. In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal. Nonsteroidal Anti-Inflammatory Agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal ant i nflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. The clearance of salicylates may be increased with concurrent use of corticosteroids. Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control. Skin Tests: Corticosteroids may suppress reactions to skin tests. Thalidomide: Co-administration with thalidomide should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use. Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see WARNINGS : Infections: Vaccination ). Carcinogenesis, Mutagenesis, Impairment of Fertility No adequate studies have been conducted in animals to determine whether corticosteroids have a potential for carcinogenesis or mutagenesis. Steroids may increase or decrease motility and number of spermatozoa in some patients. Pregnancy Teratogenic Effects: Pregnancy Category C. Corticosteroids have been shown to be teratogenic in many species when given in doses equivalent to the human dose. Animal studies in which corticosteroids have been given to pregnant mice, rats, and rabbits have yielded an increased incidence of cleft palate in the offspring. There are no adequate and well-controlled studies in pregnant women. Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Infants born to mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism. Nursing Mothers Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Because of the potential for serious adverse reactions in nursing infants from corticosteroids, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use The efficacy and safety of corticosteroids in the pediatric population are based on the we l -established course of effect of corticosteroids, which is similar in pediatric and adult populations. Published studies provide evidence of efficacy and safety in pediatric patients for the treatment of nephrotic syndrome (patients >2 years of age), and aggressive lymphomas and leukemias (patients >1 month of age). Other indications for pediatric use of corticosteroids, e.g., severe asthma and wheezing, are based on adequate and we l -controlled trials conducted in adults, on the premises that the course of the diseases and their pathophysiology are considered to be substantially similar in both populations. The adverse effects of corticosteroids in pediatric patients are similar to those in adults (see ADVERSE REACTIONS ). Like adults, pediatric patients should be carefully observed with frequent measurements of blood pressure, weight, height, intraocular pressure, and clinical evaluation for the presence of infection, psychosocial disturbances, thromboembolism, peptic ulcers, cataracts, and osteoporosis. Pediatric patients who are treated with corticosteroids by any route, including systemically administered corticosteroids, may experience a decrease in their growth velocity. This negative impact of corticosteroids on growth has been observed at low systemic doses and in the absence of laboratory evidence of hypothalamic-pituitary-adrenal (HPA) axis suppression (i.e., cosyntropin stimulation and basal cortisol plasma levels). Growth velocity may therefore be a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA axis function. The linear growth of pediatric patients treated with corticosteroids should be monitored, and the potential growth effects of prolonged treatment should be weighed against clinical benefits obtained and the availability of treatment alternatives. In order to minimize the potential growth effects of corticosteroids, pediatric patients should be titrated to the lowest effective dose. Geriatric Use Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. In particular, the increased risk of diabetes mellitus, fluid retention and hypertension in elderly patients treated with corticosteroids should be considered."],"how_supplied":["HOW SUPPLIED Dexamethasone Tablets USP, 1.5 mg are supplied as white, round shaped tablets debossed “702” on one side and bisected on the opposite side. The bisect on the tablet provides for a functional scoring of the tablet to ensure accurate breaking. They are available in bottles of: Bottles of 21 Tablets NDC: 80425-0346-01 Bottles of 27 Tablets NDC: 80425-0346-02 Bottles of 49 Tablets NDC: 80425-0346-03 Bottles of 60 Tablets NDC: 80425-0346-04 Store and Dispense Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from moisture. Dispense in a we l -closed, light-resistant container as defined in the USP/NF. Cal l your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. Distributed by: Key Therapeutics Flowood, MS 39232 Questions: (888) 981-8332 Rev. 07/2023"],"geriatric_use":["Geriatric Use Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. In particular, the increased risk of diabetes mellitus, fluid retention and hypertension in elderly patients treated with corticosteroids should be considered."],"pediatric_use":["Pediatric Use The efficacy and safety of corticosteroids in the pediatric population are based on the we l -established course of effect of corticosteroids, which is similar in pediatric and adult populations. Published studies provide evidence of efficacy and safety in pediatric patients for the treatment of nephrotic syndrome (patients >2 years of age), and aggressive lymphomas and leukemias (patients >1 month of age). Other indications for pediatric use of corticosteroids, e.g., severe asthma and wheezing, are based on adequate and we l -controlled trials conducted in adults, on the premises that the course of the diseases and their pathophysiology are considered to be substantially similar in both populations. The adverse effects of corticosteroids in pediatric patients are similar to those in adults (see ADVERSE REACTIONS ). Like adults, pediatric patients should be carefully observed with frequent measurements of blood pressure, weight, height, intraocular pressure, and clinical evaluation for the presence of infection, psychosocial disturbances, thromboembolism, peptic ulcers, cataracts, and osteoporosis. Pediatric patients who are treated with corticosteroids by any route, including systemically administered corticosteroids, may experience a decrease in their growth velocity. This negative impact of corticosteroids on growth has been observed at low systemic doses and in the absence of laboratory evidence of hypothalamic-pituitary-adrenal (HPA) axis suppression (i.e., cosyntropin stimulation and basal cortisol plasma levels). Growth velocity may therefore be a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA axis function. The linear growth of pediatric patients treated with corticosteroids should be monitored, and the potential growth effects of prolonged treatment should be weighed against clinical benefits obtained and the availability of treatment alternatives. In order to minimize the potential growth effects of corticosteroids, pediatric patients should be titrated to the lowest effective dose."],"effective_time":"20251029","nursing_mothers":["Nursing Mothers Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Because of the potential for serious adverse reactions in nursing infants from corticosteroids, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother."],"adverse_reactions":["ADVERSE REACTIONS (listed alphabetica ll y, under each subsection) The following adverse reactions have been reported with dexamethasone or other corticosteroids: A ll ergic Reactions: Anaphylactoid reaction, anaphylaxis, angioedema. Cardiovascular: Bradycardia, cardiac arrest, cardiac arrhythmias, cardiac enlargement, circulatory co l apse, congestive heart failure, fat embolism, hypertension, hypertrophic cardiomyopathy in premature infants, myocardial rupture following recent myocardial infarction (see WARNINGS: Cardio-Renal ), edema, pulmonary edema, syncope, tachycardia, thromboembolism, thrombophlebitis, vasculitis. Dermatologic: Acne, allergic dermatitis, dry scaly skin, ecchymoses and petechiae, erythema, impaired wound healing, increased sweating, rash, striae, suppression of reactions to skin tests, thin fragile skin, thinning scalp hair, urticaria. Endocrine: Decreased carbohydrate and glucose tolerance, development of cushingoid state, hyperglycemia, glycosuria, hirsutism, hypertrichosis, increased requirements for insulin or oral hypoglycemic agents in diabetes, manifestations of latent diabetes mellitus, menstrual irregularities, secondary adrenocortical and pituitary unresponsiveness (particularly in times of stress, as in trauma, surgery, or ill ness), suppression of growth in pediatric patients. Fluid and Electrolyte Disturbances: Congestive heart failure in susceptible patients, fluid retention, hypokalemic alkalosis, potassium loss, sodium retention, tumor lysis syndrome. Gastrointestinal: Abdominal distention, elevation in serum liver enzyme levels (usually reversible upon discontinuation), hepatomegaly, increased appetite, nausea, pancreatitis, peptic ulcer with possible perforation and hemorrhage, perforation of the small and large intestine (particularly in patients with inflammatory bowel disease), ulcerative esophagitis. Metabolic: Negative nitrogen balance due to protein catabolism. Musculoskeletal: Aseptic necrosis of femoral and humeral heads, loss of muscle mass, muscle weakness, osteoporosis, pathologic fracture of long bones, steroid myopathy, tendon rupture, vertebral compression fractures. Neurological/Psychiatric: Convulsions, depression, emotional instability, euphoria, headache, increased intracranial pressure with papilledema (pseudotumor cerebri) usually following discontinuation of treatment, insomnia, mood swings, neuritis, neuropathy, paresthesia, personality changes, psychic disorders, vertigo. Ophthalmic: Exophthalmos, glaucoma, increased intraocular pressure, posterior subcapsular cataracts. Other: Abnormal fat deposits, decreased resistance to infection, hiccups, increased or decreased motility and number of spermatozoa, malaise, moon face, weight gain."],"contraindications":["CONTRAINDICATIONS Contraindicated in systemic fungal infections (see WARNINGS : Infections: Fungal Infections ) and patients with known hypersensitivity to the product and its consituents."],"drug_interactions":["Drug Interactio ns Aminoglutethimide: Aminoglutethimide may diminish adrenal suppression by corticosteroids. Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure. Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance (see Drug Interactions: Hepatic Enzyme Inducers, Inhibitors and Substrates ). Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy. Anticoagulants, Oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. Antitubercular Drugs: Serum concentrations of isoniazid may be decreased. Cholestyramine: Cholestyramine may increase the clearance of corticosteroids. Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently. Convulsions have been reported with this concurrent use. Dexamethasone Suppression Test (DST): False-negative results in the dexamethasone suppression test (DST) in patients being treated with indomethacin have been reported. Thus, results of the DST should be interpreted with caution in these patients. Digitalis Glycosides: Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia. Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage. Estrogens, including Oral Contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids. Dexamethasone is a moderate inducer of CYP 3A4. Co-adminstration with other drugs that are metabolized by CYP 3A4 (e.g., indinavir, erythromycin) may increase their clearance, resulting in decreased plasma concentration. Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects. In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal. Nonsteroidal Anti-Inflammatory Agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal ant i nflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. The clearance of salicylates may be increased with concurrent use of corticosteroids. Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control. Skin Tests: Corticosteroids may suppress reactions to skin tests. Thalidomide: Co-administration with thalidomide should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use. Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see WARNINGS : Infections: Vaccination )."],"general_precautions":["General Rare instances of anaphylactoid reactions have occurred in patients receiving corticosteroid therapy (see ADVERSE REACTIONS ). Increased dosage of rapidly acting corticosteroids is indicated in patients on corticosteroid therapy subjected to any unusual stress before, during, and after the stressful situation.","General The lowest possible dose of corticosteroids should be used to control the condition under treatment. When reduction in dosage is possible, the reduction should be gradual. Since complications of treatment with corticosteroids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used. Kaposi's sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement. Cardio- Renal As sodium retention with resultant edema and potassium loss may occur in patients receiving corticosteroids, these agents should be used with caution in patients with congestive heart failure, hypertension, or renal insufficiency. Endocrine Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently. Gastrointestinal Steroids should be used with caution in active or latent peptic ulcers, diverticulitis, fresh intestinal anastomoses, and nonspecific ulcerative colitis, since they may increase the risk of a perforation. Signs of peritoneal irritation following gastrointestinal perforation in patients receiving corticosteroids may be minimal or absent. There is an enhanced effect due to decreased metabolism of corticosteroids in patients with cirrhosis. Musculoskeletal Corticosteroids decrease bone formation and increase bone resorption both through their effect on calcium regulation (i.e., decreasing absorption and increasing excretion) and inhibition of osteoblast function. This, together with a decrease in the protein matrix of the bone secondary to an increase in protein catabolism, and reduced sex hormone production, may lead to inhibition of bone growth in pediatric patients and the development of osteoporosis at any age. Special consideration should be given to patients at increased risk of osteoporosis (e.g., postmenopausal women) before initiating corticosteroid therapy. Neuro-Psychiatric Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis, they do not show that they affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect. (see DOSAGE AND ADMINISTRATION ). An acute myopathy has been observed with the use of high doses of corticosteroids, most often occurring in patients with disorders of neuromuscular transmission (e.g., myasthenia gravis), or in patients receiving concomitant therapy with neuromuscular blocking drugs (e.g., pancuronium). This acute myopathy is generalized, may involve ocular and respiratory muscles, and may result in quadriparesis. Elevation of creatinine kinase may occur. Clinical improvement or recovery after stopping corticosteroids may require weeks to years. Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids. Ophthalmic lntraocular pressure may become elevated in some individuals. If steroid therapy is continued for more than 6 weeks, intraocular pressure should be monitored."],"inactive_ingredient":["INACTIVE INGREDIENT Dexamethasone Tablets USP, 1.5 mg contain lactose monohydrate, magnesium stearate, starch and compressible sugar. Dexamethasone, a synthetic adrenocortical steroid, is a white to practical l y white, odorless, crystalline powder. It is stable in air. It is practically insoluble in water. The molecular formula is C 22 H 29 FO 5 . The molecular weight is 392.47. It is designated chemically as 9-fluoro-11β,17,21-trihydroxy-16α- methylpregna-1,4-diene-3,20-dione and the structural formula is: structural formula"],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Glucocorticoids cause varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have sodium-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs, including dexamethasone, are primarily used for their anti-inflammatory effects in disorders of many organ systems. At equipotent anti-inflammatory doses, dexamethasone almost completely lacks the sodium-retaining property of hydrocortisone and closely related derivatives of hydrocortisone."],"indications_and_usage":["INDICATIONS AND USAGE A l l ergic States: Control of severe or incapacitating a llergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases: Bul l ous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Misce l l aneous: Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases: For the palliative management of leukemias and lymphomas. Nervous System: Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases: To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus."],"safe_handling_warning":["OVERDOSAGE Treatment of overdosage is by supportive and symptomatic therapy. In the case of acute overdosage, according to the patient's condition, supportive therapy may include gastric lavage or emesis."],"information_for_patients":["Information for Patients Patients should be warned not to discontinue the use of corticosteroids abruptly or without medical supervision. As prolonged use may cause adrenal insufficiency and make patients dependent on corticosteroids, they should advise any medical attendants that they are taking corticosteroids and they should seek medical advice at once should they develop an acute illness including fever or other signs of infection. Following prolonged therapy, withdrawal of corticosteroids may result in symptoms of the corticosteroid withdrawal syndrome including, myalgia, arthralgia, and malaise. Persons who are on corticosteroids should be warned to avoid exposure to chickenpox or measles. Patients should also be advised that if they are exposed, medical advice should be sought without delay."],"spl_unclassified_section":["DEXAMETHASONE Tablets USP, 1.5 mg Rx Only"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION For Oral Administration The initial dosage varies from 0.75 to 9 mg a day depending on the disease being treated. It Should Be Emphasized That Dosage Requirements Are Variable And Must Be Individualized On The Basis Of The Disease Under Treatment And The Response Of The Patient. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage that maintains an adequate clinical response is reached. Situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment. In this latter situation it may be necessary to increase the dosage of the corticosteroid for a period of time consistent with the patient's condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly. In the treatment of acute exacerbations of multiple sclerosis, daily doses of 30 mg of dexamethasone for a week followed by 4 to 12 mg every other day for one month have been shown to be effective (see PRECAUTIONS : Neuro-Psychiatric ). In pediatric patients, the initial dose of dexamethasone may vary depending on the specific disease entity being treated. The range of initial doses is 0.02 to 0.3 mg/kg/day in three or four divided doses (0.6 to 9 mg/m2bsa/day). For the purpose of comparison, the fo ll owing is the equivalent mi lli gram dosage of the various corticosteroids: Dexamethasone, 1.5 Methylprednisolone, 8 Prednisone, 10 Triamcinolone, 8 Prednisolone, 10 Betamethasone, 1.5 Hydrocortisone, 40 Paramethasone, 4 Cortisone, 50 These dose relationships apply only to oral or intravenous administration of these compounds. When these substances or their derivatives are injected intramuscularly or into joint spaces, their relative properties may be greatly altered. In acute, self-limited allergic disorders or acute exacerbations of chronic allergic disorders, the following dosage schedule combining parenteral and oral therapy is suggested: Dexamethasone sodium phosphate injection, 4 mg per mL First Day 1 or 2 mL, intramuscularly Dexamethasone tablets, 0.75 mg Second Day 4 tablets in two divided doses Third Day 4 tablets in two divided doses Fourth Day 2 tablets in two divided doses Fifth Day 1 tablet Sixth Day 1 tablet Seventh Day No treatment Eighth Day Follow-up visit This schedule is designed to ensure adequate therapy during acute episodes, while minimizing the risk of overdosage in chronic cases. In cerebral edema , dexamethasone sodium phosphate injection is generally administered initially in a dosage of 10 mg intravenously followed by 4 mg every six hours intramuscularly until the symptoms of cerebral edema subside. Response is usually noted within 12 to 24 hours and dosage may be reduced after two to four days and gradually discontinued over a period of five to seven days. For pal l iative management of patients with recurrent or inoperable brain tumors, maintenance therapy with either dexamethasone sodium phosphate injection or dexamethasone tablets in a dosage of 2 mg two or three times daily may be effective. Dexamethasone Suppression Tests 1. Tests for Cushing’s syndrome Give 1.0 mg of dexamethasone orally at 11:00 p.m. Blood is drawn for plasma cortisol determination at 8:00 a.m. the following morning. For greater accuracy, give 0.5 mg of dexamethasone orally every 6 hours for 48 hours. Twenty-four hour urine co l ections are made for determination of 17-hydroxycorticosteroid excretion. 2. Test to distinguish Cushing’s syndrome due to pituitary ACTH excess from Cushing’s syndrome due to other causes. Give 2.0 mg of dexamethasone orally every 6 hours for 48 hours. Twenty-four hour urine co l ections are made for determination of 17-hydroxycorticosteroid excretion."],"spl_product_data_elements":["Dexamethasone Dexamethasone LACTOSE MONOHYDRATE MAGNESIUM STEARATE STARCH, CORN SUCROSE DEXAMETHASONE DEXAMETHASONE 702"],"package_label_principal_display_panel":["Principal Display Panel label 1 Dexamethasone 1.5mg Tablet #27 Dexamethasone 1.5mg Tablet # 27 Dexamethasone 1.5mg Tablet # 60"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility No adequate studies have been conducted in animals to determine whether corticosteroids have a potential for carcinogenesis or mutagenesis. Steroids may increase or decrease motility and number of spermatozoa in some patients."]},"tags":[],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"22581 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"17010 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"16997 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"14154 reports"},{"date":"","signal":"PLASMA CELL MYELOMA","source":"FDA FAERS","actionTaken":"13926 reports"},{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"13698 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"13362 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"13093 reports"},{"date":"","signal":"NEUTROPENIA","source":"FDA FAERS","actionTaken":"11525 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"11174 reports"}],"drugInteractions":[{"drug":"Aminoglutethimide","severity":"","mechanism":"Diminishes adrenal suppression by corticosteroids","management":"","clinicalEffect":"Reduced corticosteroid effect"},{"drug":"Amphotericin B injection and potassium-depleting agents","severity":"","mechanism":"Concomitant use may cause hypokalemia; cases of cardiac enlargement and congestive heart failure reported with amphotericin B and hydrocortisone","management":"Observe patients closely for development of hypokalemia","clinicalEffect":"Hypokalemia, cardiac enlargement, congestive heart failure"},{"drug":"Macrolide antibiotics","severity":"","mechanism":"Significant decrease in corticosteroid clearance","management":"","clinicalEffect":"Increased corticosteroid levels"},{"drug":"Anticholinesterase agents","severity":"","mechanism":"Concomitant use may produce severe weakness","management":"Withdraw anticholinesterase agents at least 24 hours before initiating corticosteroid therapy if possible","clinicalEffect":"Severe weakness in patients with myasthenia gravis"},{"drug":"Warfarin","severity":"","mechanism":"Corticosteroids usually inhibit response to warfarin","management":"Monitor coagulation indices frequently to maintain desired anticoagulant effect","clinicalEffect":"Reduced anticoagulant effect"},{"drug":"Antidiabetic agents","severity":"","mechanism":"Corticosteroids may increase blood glucose concentrations","management":"Dosage adjustments of antidiabetic agents may be required","clinicalEffect":"Hyperglycemia"},{"drug":"Isoniazid","severity":"","mechanism":"Serum concentrations may be decreased","management":"","clinicalEffect":"Reduced isoniazid levels"},{"drug":"Cholestyramine","severity":"","mechanism":"May increase clearance of corticosteroids","management":"","clinicalEffect":"Reduced corticosteroid levels"},{"drug":"Cyclosporine","severity":"","mechanism":"Increased activity of both cyclosporine and corticosteroids; convulsions reported","management":"","clinicalEffect":"Increased drug activity, convulsions"},{"drug":"Indomethacin","severity":"","mechanism":"False-negative results in dexamethasone suppression test","management":"Interpret DST results with caution in patients treated with indomethacin","clinicalEffect":"Unreliable DST results"}],"commonSideEffects":[{"effect":"Infections and infestations - Other, specify","drugRate":"24.5%","placeboRate":"","totalAtRisk":1524,"totalAffected":374,"trialsReporting":2},{"effect":"Neutrophil count decreased","drugRate":"23.0%","placeboRate":"","totalAtRisk":1524,"totalAffected":350,"trialsReporting":2},{"effect":"Febrile neutropenia","drugRate":"19.3%","placeboRate":"","totalAtRisk":1524,"totalAffected":294,"trialsReporting":2},{"effect":"Alanine aminotransferase increased","drugRate":"17.7%","placeboRate":"","totalAtRisk":1524,"totalAffected":270,"trialsReporting":2},{"effect":"Platelet count decreased","drugRate":"13.4%","placeboRate":"","totalAtRisk":1524,"totalAffected":204,"trialsReporting":2},{"effect":"White blood cell decreased","drugRate":"12.9%","placeboRate":"","totalAtRisk":1524,"totalAffected":197,"trialsReporting":2},{"effect":"Anemia","drugRate":"10.3%","placeboRate":"","totalAtRisk":1524,"totalAffected":157,"trialsReporting":2},{"effect":"Hyponatremia","drugRate":"7.3%","placeboRate":"","totalAtRisk":1524,"totalAffected":111,"trialsReporting":2},{"effect":"Hyperglycemia","drugRate":"6.9%","placeboRate":"","totalAtRisk":1524,"totalAffected":105,"trialsReporting":2},{"effect":"Aspartate aminotransferase increased","drugRate":"6.8%","placeboRate":"","totalAtRisk":1524,"totalAffected":103,"trialsReporting":2},{"effect":"Hypokalemia","drugRate":"6.6%","placeboRate":"","totalAtRisk":1524,"totalAffected":100,"trialsReporting":2},{"effect":"Hypocalcemia","drugRate":"3.9%","placeboRate":"","totalAtRisk":1524,"totalAffected":59,"trialsReporting":2},{"effect":"Fibrinogen decreased","drugRate":"3.7%","placeboRate":"","totalAtRisk":1524,"totalAffected":57,"trialsReporting":2},{"effect":"Peripheral motor neuropathy","drugRate":"3.3%","placeboRate":"","totalAtRisk":1524,"totalAffected":50,"trialsReporting":2},{"effect":"Hypoalbuminemia","drugRate":"3.0%","placeboRate":"","totalAtRisk":1524,"totalAffected":45,"trialsReporting":2},{"effect":"Diarrhea","drugRate":"2.8%","placeboRate":"","totalAtRisk":1524,"totalAffected":42,"trialsReporting":2},{"effect":"Peripheral sensory neuropathy","drugRate":"2.6%","placeboRate":"","totalAtRisk":1524,"totalAffected":40,"trialsReporting":2},{"effect":"Hypertension","drugRate":"2.4%","placeboRate":"","totalAtRisk":1524,"totalAffected":37,"trialsReporting":2},{"effect":"Abdominal pain","drugRate":"2.4%","placeboRate":"","totalAtRisk":1524,"totalAffected":36,"trialsReporting":2},{"effect":"Lipase increased","drugRate":"2.4%","placeboRate":"","totalAtRisk":1524,"totalAffected":36,"trialsReporting":2},{"effect":"Blood bilirubin increased","drugRate":"2.3%","placeboRate":"","totalAtRisk":1524,"totalAffected":35,"trialsReporting":2},{"effect":"Anaphylaxis","drugRate":"2.2%","placeboRate":"","totalAtRisk":1524,"totalAffected":34,"trialsReporting":2},{"effect":"Lung infection","drugRate":"2.2%","placeboRate":"","totalAtRisk":1524,"totalAffected":33,"trialsReporting":2},{"effect":"Upper respiratory infection","drugRate":"2.2%","placeboRate":"","totalAtRisk":1524,"totalAffected":33,"trialsReporting":2},{"effect":"GGT increased","drugRate":"2.2%","placeboRate":"","totalAtRisk":1524,"totalAffected":33,"trialsReporting":2},{"effect":"Fever","drugRate":"2.1%","placeboRate":"","totalAtRisk":1524,"totalAffected":32,"trialsReporting":2},{"effect":"Anorexia","drugRate":"2.1%","placeboRate":"","totalAtRisk":1524,"totalAffected":32,"trialsReporting":2},{"effect":"Mucositis oral","drugRate":"2.0%","placeboRate":"","totalAtRisk":1524,"totalAffected":31,"trialsReporting":2},{"effect":"Dehydration","drugRate":"1.8%","placeboRate":"","totalAtRisk":1524,"totalAffected":28,"trialsReporting":2},{"effect":"Vomiting","drugRate":"1.8%","placeboRate":"","totalAtRisk":1524,"totalAffected":27,"trialsReporting":2},{"effect":"Hyperkalemia","drugRate":"1.8%","placeboRate":"","totalAtRisk":1524,"totalAffected":27,"trialsReporting":2},{"effect":"Hypoxia","drugRate":"1.8%","placeboRate":"","totalAtRisk":1524,"totalAffected":27,"trialsReporting":2},{"effect":"Hypophosphatemia","drugRate":"1.7%","placeboRate":"","totalAtRisk":1524,"totalAffected":26,"trialsReporting":2},{"effect":"Catheter related infection","drugRate":"1.6%","placeboRate":"","totalAtRisk":1524,"totalAffected":24,"trialsReporting":2},{"effect":"Lymphocyte count decreased","drugRate":"1.5%","placeboRate":"","totalAtRisk":1524,"totalAffected":23,"trialsReporting":2},{"effect":"Pancreatitis","drugRate":"1.4%","placeboRate":"","totalAtRisk":1524,"totalAffected":21,"trialsReporting":2},{"effect":"Enterocolitis infectious","drugRate":"1.4%","placeboRate":"","totalAtRisk":1524,"totalAffected":21,"trialsReporting":2},{"effect":"Activated partial thromboplastin time prolonged","drugRate":"1.4%","placeboRate":"","totalAtRisk":1524,"totalAffected":21,"trialsReporting":2},{"effect":"Serum amylase increased","drugRate":"1.4%","placeboRate":"","totalAtRisk":1524,"totalAffected":21,"trialsReporting":2},{"effect":"Weight loss","drugRate":"1.2%","placeboRate":"","totalAtRisk":1524,"totalAffected":18,"trialsReporting":2},{"effect":"Pain in extremity","drugRate":"1.2%","placeboRate":"","totalAtRisk":1524,"totalAffected":18,"trialsReporting":2},{"effect":"Thromboembolic event","drugRate":"1.2%","placeboRate":"","totalAtRisk":1524,"totalAffected":18,"trialsReporting":2},{"effect":"Constipation","drugRate":"1.1%","placeboRate":"","totalAtRisk":1524,"totalAffected":17,"trialsReporting":2},{"effect":"Skin infection","drugRate":"1.1%","placeboRate":"","totalAtRisk":1524,"totalAffected":17,"trialsReporting":2},{"effect":"Otitis media","drugRate":"1.0%","placeboRate":"","totalAtRisk":1524,"totalAffected":16,"trialsReporting":2},{"effect":"Muscle weakness lower limb","drugRate":"1.0%","placeboRate":"","totalAtRisk":1524,"totalAffected":16,"trialsReporting":2},{"effect":"Tumor lysis syndrome","drugRate":"1.0%","placeboRate":"","totalAtRisk":1524,"totalAffected":15,"trialsReporting":2},{"effect":"Seizure","drugRate":"1.0%","placeboRate":"","totalAtRisk":1524,"totalAffected":15,"trialsReporting":2},{"effect":"Hypotension","drugRate":"1.0%","placeboRate":"","totalAtRisk":1524,"totalAffected":15,"trialsReporting":2},{"effect":"Nausea","drugRate":"0.9%","placeboRate":"","totalAtRisk":1524,"totalAffected":14,"trialsReporting":2}],"contraindications":["Systemic fungal infections","Known hypersensitivity to dexamethasone and its constituents"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"approved","trials":["NCT00213226","NCT06006091","NCT06536491","NCT00880191","NCT01941680","NCT05631405","NCT05387941","NCT01078454","NCT00991744","NCT01527032","NCT06263907","NCT05852717","NCT06979596","NCT00111072","NCT00261612","NCT01969565","NCT04783194","NCT07513129","NCT01960530","NCT03942601","NCT06627751","NCT00097981","NCT03605719","NCT02666209","NCT00711555","NCT07068230","NCT00866307","NCT04940338","NCT03889444","NCT02623426","NCT06407544","NCT03326544","NCT06131593","NCT04270409","NCT02079649","NCT02320006","NCT02991404","NCT00825071","NCT05393726","NCT07425678","NCT06307444","NCT03383328","NCT04540133","NCT06658418","NCT02514382","NCT05232825","NCT00910897","NCT03220113","NCT04065308","NCT02304250"],"aliases":["Decadron","DexPak"],"patents":[{"type":"Method of Use","number":"10028965","applicant":"EYEPOINT PHARMACEUTICALS INC","territory":"US","tradeName":"DEXYCU KIT","expiryDate":"2034-05-23"},{"type":"Method of Use","number":"8563027","applicant":"OCULAR THERAPEUTIX INC","territory":"US","tradeName":"DEXTENZA","expiryDate":"2030-02-12"},{"type":"Method of Use","number":"12144889","applicant":"OCULAR THERAPEUTIX INC","territory":"US","tradeName":"DEXTENZA","expiryDate":"2041-04-26"},{"type":"Method of Use","number":"12150896","applicant":"OCULAR THERAPEUTIX INC","territory":"US","tradeName":"DEXTENZA","expiryDate":"2036-10-07"},{"type":"Formulation","number":"11097061","applicant":"EYEPOINT PHARMACEUTICALS INC","territory":"US","tradeName":"DEXYCU KIT","expiryDate":"2039-06-23"},{"type":"Method of Use","number":"10022502","applicant":"EYEPOINT PHARMACEUTICALS INC","territory":"US","tradeName":"DEXYCU KIT","expiryDate":"2034-06-22"},{"type":"Method of Use","number":"11458041","applicant":"OCULAR THERAPEUTIX INC","territory":"US","tradeName":"DEXTENZA","expiryDate":"2037-11-16"},{"type":"Formulation","number":"11304961","applicant":"DEXCEL PHARMA TECHNOLOGIES LTD","territory":"US","tradeName":"HEMADY","expiryDate":"2037-12-18"},{"type":"Formulation","number":"8409606","applicant":"OCULAR THERAPEUTIX INC","territory":"US","tradeName":"DEXTENZA","expiryDate":"2030-05-14"},{"type":"Formulation","number":"10799642","applicant":"EYEPOINT PHARMACEUTICALS INC","territory":"US","tradeName":"DEXYCU KIT","expiryDate":"2032-05-11"},{"type":"Formulation","number":"10159683","applicant":"EYEPOINT PHARMACEUTICALS INC","territory":"US","tradeName":"DEXYCU KIT","expiryDate":"2034-05-23"},{"type":"Formulation","number":"10537585","applicant":"DEXCEL PHARMA TECHNOLOGIES LTD","territory":"US","tradeName":"HEMADY","expiryDate":"2037-12-18"}],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$7.2702/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$2,617","description":"DEXAMETHASONE 0.1% EYE DROP","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=dexamethasone","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:37:32.758686+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T23:37:32.758072+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:37:39.729431+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:37:31.354411+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=dexamethasone","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:37:40.638325+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:37:29.604481+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:37:29.604518+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:37:29.604525+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:37:42.228836+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1697787/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:37:41.091588+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA201270","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:37:29.604531+00:00"}},"allNames":"decadron","offLabel":[],"timeline":[],"aiSummary":"Dexamethasone is the most potent commonly used corticosteroid, approved in 1958. The RECOVERY trial (2020) proved it reduces COVID-19 mortality in severe cases, making it one of the most important drugs in the pandemic response. Available generically worldwide at very low cost.","brandName":"Decadron","companyId":"unknown","ecosystem":[],"mechanism":{"target":"Annexin A1, Interleukin-4, Androgen receptor","novelty":"","modality":"Small molecule","drugClass":"Corticosteroid [EPC]","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"_validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T08:32:54.255024+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"companyName":"Generic (originally Merck)","competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"dexamethasone","indications":{"approved":[{"name":"Acquired thrombocytopenia","diseaseId":"acquired-thrombocytopenia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Acute lymphoid leukemia","diseaseId":"acute-lymphoid-leukemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Adrenal cortical hypofunction","diseaseId":"adrenal-cortical-hypofunction","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Adrenogenital disorder","diseaseId":"adrenogenital-disorder","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Allergic conjunctivitis","diseaseId":"allergic-conjunctivitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Allergic otitis externa","diseaseId":"allergic-otitis-externa","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Allergic rhinitis","diseaseId":"allergic-rhinitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Angioedema","diseaseId":"angioedema","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Ankylosing spondylitis","diseaseId":"ankylosing-spondylitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Anterior uveitis","diseaseId":"anterior-uveitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Articular gout","diseaseId":"articular-gout","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Asthma","diseaseId":"asthma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Atopic dermatitis","diseaseId":"atopic-dermatitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Autoimmune hemolytic anemia","diseaseId":"autoimmune-hemolytic-anemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bacterial keratitis","diseaseId":"bacterial-keratitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Berylliosis","diseaseId":"berylliosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Blepharoconjunctivitis","diseaseId":"blepharoconjunctivitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Branch retinal vein occlusion with macular edema","diseaseId":"branch-retinal-vein-occlusion-with-macular-edema","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Burkitt's lymphoma","diseaseId":"burkitt's-lymphoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bursitis","diseaseId":"bursitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Central retinal vein occlusion with macular edema","diseaseId":"central-retinal-vein-occlusion-with-macular-edema","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Cerebral edema","diseaseId":"cerebral-edema","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Congenital hypoplastic anemia","diseaseId":"congenital-hypoplastic-anemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Contact dermatitis","diseaseId":"contact-dermatitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Corneal abrasion","diseaseId":"corneal-abrasion","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Corneal ulcer","diseaseId":"corneal-ulcer","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Crohn's disease","diseaseId":"crohn's-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Cyclitis","diseaseId":"cyclitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Dermatitis herpetiformis","diseaseId":"dermatitis-herpetiformis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Diagnostic Test for Cushing's Syndrome","diseaseId":"diagnostic-test-for-cushing's-syndrome","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Diffuse non-Hodgkin's lymphoma, large cell","diseaseId":"diffuse-non-hodgkin's-lymphoma-large-cell","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Discoid lupus erythematosus","diseaseId":"discoid-lupus-erythematosus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Disorder of eye","diseaseId":"disorder-of-eye","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Disorder of musculoskeletal system","diseaseId":"disorder-of-musculoskeletal-system","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Disorder of skin","diseaseId":"disorder-of-skin","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Edema of larynx","diseaseId":"edema-of-larynx","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Epicondylitis","diseaseId":"epicondylitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Eruption of skin","diseaseId":"eruption-of-skin","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Erythema multiforme","diseaseId":"erythema-multiforme","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Erythroblastic Anemia","diseaseId":"erythroblastic-anemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Erythroderma","diseaseId":"erythroderma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Exacerbation of asthma","diseaseId":"exacerbation-of-asthma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Follicular non-Hodgkin's lymphoma","diseaseId":"follicular-non-hodgkin's-lymphoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Granuloma annulare","diseaseId":"granuloma-annulare","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Herpes zoster keratitis","diseaseId":"herpes-zoster-keratitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Hodgkin's disease","diseaseId":"hodgkin's-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Humoral hypercalcemia of malignancy","diseaseId":"humoral-hypercalcemia-of-malignancy","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Idiopathic thrombocytopenic purpura","diseaseId":"idiopathic-thrombocytopenic-purpura","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infection by larvae of Trichinella spiralis","diseaseId":"infection-by-larvae-of-trichinella-spiralis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infective blepharitis","diseaseId":"infective-blepharitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infective otitis media","diseaseId":"infective-otitis-media","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Inflammatory bowel disease","diseaseId":"inflammatory-bowel-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Iridocyclitis","diseaseId":"iridocyclitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Iritis","diseaseId":"iritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Keloid scar","diseaseId":"keloid-scar","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Keratitis","diseaseId":"keratitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Lichen simplex chronicus","diseaseId":"lichen-simplex-chronicus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Löffler's syndrome","diseaseId":"löffler's-syndrome","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Malignant otitis externa due to Pseudomonas aeruginosa","diseaseId":"malignant-otitis-externa-due-to-pseudomonas-aeruginosa","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Miliary tuberculosis","diseaseId":"miliary-tuberculosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Multiple myeloma","diseaseId":"multiple-myeloma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Multiple sclerosis","diseaseId":"multiple-sclerosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Mycosis fungoides","diseaseId":"mycosis-fungoides","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Nephrotic syndrome","diseaseId":"nephrotic-syndrome","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Non-Hodgkin's lymphoma","diseaseId":"non-hodgkin's-lymphoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Non-infectious Posterior Uveitis","diseaseId":"non-infectious-posterior-uveitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Otitis Externa Eczema","diseaseId":"otitis-externa-eczema","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Otitis Externa Seborrhea","diseaseId":"otitis-externa-seborrhea","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Otitis externa","diseaseId":"otitis-externa","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pemphigus","diseaseId":"pemphigus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Perforation of cornea","diseaseId":"perforation-of-cornea","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Plaque psoriasis","diseaseId":"plaque-psoriasis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Post-Op Ocular Inflammation","diseaseId":"post-op-ocular-inflammation","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Primary adrenocortical insufficiency","diseaseId":"primary-adrenocortical-insufficiency","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Primary cutaneous T-cell lymphoma","diseaseId":"primary-cutaneous-t-cell-lymphoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Progressive Diffuse Large B-Cell Lymphoma","diseaseId":"progressive-diffuse-large-b-cell-lymphoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pruritus ani","diseaseId":"pruritus-ani","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pruritus of genital organs","diseaseId":"pruritus-of-genital-organs","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Psoriasis","diseaseId":"psoriasis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Psoriasis with arthropathy","diseaseId":"psoriasis-with-arthropathy","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Punctate keratitis","diseaseId":"punctate-keratitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Punctate keratopathy","diseaseId":"punctate-keratopathy","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Rheumatic heart disease","diseaseId":"rheumatic-heart-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Rheumatoid arthritis","diseaseId":"rheumatoid-arthritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Rosacea","diseaseId":"rosacea","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Sarcoidosis","diseaseId":"sarcoidosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Scalp psoriasis","diseaseId":"scalp-psoriasis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Seborrheic dermatitis","diseaseId":"seborrheic-dermatitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Severe adrenal insufficiency","diseaseId":"severe-adrenal-insufficiency","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Staphylococcus Aureus Otitis Externa","diseaseId":"staphylococcus-aureus-otitis-externa","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Synovitis due to Osteoarthritis","diseaseId":"synovitis-due-to-osteoarthritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Systemic AL amyloidosis","diseaseId":"systemic-al-amyloidosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Systemic Dermatomyositis","diseaseId":"systemic-dermatomyositis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Systemic lupus erythematosus","diseaseId":"systemic-lupus-erythematosus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Tenosynovitis","diseaseId":"tenosynovitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Thyroiditis","diseaseId":"thyroiditis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Transfusion Reaction Urticaria","diseaseId":"transfusion-reaction-urticaria","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Transfusion reaction due to serum protein reaction","diseaseId":"transfusion-reaction-due-to-serum-protein-reaction","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Transplanted organ rejection","diseaseId":"transplanted-organ-rejection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Tuberculosis Meningitis Treatment Adjunct","diseaseId":"tuberculosis-meningitis-treatment-adjunct","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Uveitis","diseaseId":"uveitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00213226","phase":"Phase 3","title":"Efficacy of Single Dose Versus Multiple Doses of Dexamethasone in Outpatients With Acute Bronchiolitis","status":"COMPLETED","sponsor":"The Hospital for Sick Children","isPivotal":true,"enrollment":120,"indication":"Bronchiolitis","completionDate":"2006-04"},{"nctId":"NCT06006091","phase":"NA","title":"Clinical Outcomes of Letrozole-induced Endometrial Preparation Regimens Versus Conventional Endometrial Preparation Regimens Including Natural Cycle, Hormone Replacement Regimens in FET, a Randomized ","status":"RECRUITING","sponsor":"International Peace Maternity and Child Health Hospital","isPivotal":false,"enrollment":858,"indication":"Letrozole, Infertility, Female","completionDate":"2027-08-01"},{"nctId":"NCT06536491","phase":"Phase 1","title":"A Randomized, Controlled, Subject- and Evaluator-Masked, Phase 2 Clinical Trial Comparing EC-104 Intravitreal Implant to Ozurdex® for the Treatment of Diabetic Macular Edema (BETTIS-1)","status":"RECRUITING","sponsor":"Eclipse Life Sciences, Inc.","isPivotal":false,"enrollment":75,"indication":"Diabetic Macular Edema","completionDate":"2025-12-31"},{"nctId":"NCT00880191","phase":"Phase 3","title":"Phase III Double-Blind, Placebo-Controlled Study of Gabapentin for the Prevention of Delayed CINV (Chemotherapy Induced Nausea and Vomiting) in Patients Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","isPivotal":true,"enrollment":430,"indication":"Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific","completionDate":"2015-05"},{"nctId":"NCT01941680","phase":"N/A","title":"Observational Prospective Study, Evaluating the Standard of Care as Recommend by International Consensus With Zidovudine-Pegylated Interferon +/-Polychemotherapy in High Risk Adult-T-cell Lymphoma/Leu","status":"COMPLETED","sponsor":"University Hospital Center of Martinique","isPivotal":false,"enrollment":20,"indication":"T-cell Lymphoma, Leukaemia","completionDate":"2021-03"},{"nctId":"NCT05631405","phase":"NA","title":"Efficacy of Dengue Infection With Warning Signs Treated With Dexamethasone","status":"RECRUITING","sponsor":"Chulalongkorn University","isPivotal":false,"enrollment":200,"indication":"Severe Dengue","completionDate":"2026-12-31"},{"nctId":"NCT05387941","phase":"Phase 1","title":"Pharmacokinetics and Safety of Dexamethasone Eye Drops in Preterm Infants With Retinopathy of Prematurity- a Feasibility Study","status":"RECRUITING","sponsor":"Region Skane","isPivotal":false,"enrollment":15,"indication":"Retinopathy of Prematurity","completionDate":"2028-12"},{"nctId":"NCT01078454","phase":"Phase 3","title":"A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients With Systemic Light-Chain (AL) Amyloidosis Ineligible f","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":true,"enrollment":11,"indication":"Light Chain Deposition Disease, Primary Systemic Amyloidosis","completionDate":"2012-11-27"},{"nctId":"NCT00991744","phase":"Phase 3","title":"Phase III Randomised Study on Liposomal Cytarabine (DepoCyte®) vs. Intrathecal Triple for CNS-Treatment During Maintenance Therapy in High-Risk Acute Lymphoblastic Leukemia Patients in NOPHO ALL 2008 ","status":"SUSPENDED","sponsor":"Nordic Society for Pediatric Hematology and Oncology","isPivotal":true,"enrollment":100,"indication":"Acute Lymphoblastic Leukemia","completionDate":"2018-12"},{"nctId":"NCT01527032","phase":"Phase 2","title":"Risk-adapted Therapy for AL Amyloidosis","status":"COMPLETED","sponsor":"FDA Office of Orphan Products Development","isPivotal":false,"enrollment":0,"indication":"Amyloidosis","completionDate":"2005-09"},{"nctId":"NCT06263907","phase":"NA","title":"Preemptive Efficacy of Stellate Ganglion Block for Prevention of Post Mastectomy Depression","status":"RECRUITING","sponsor":"Mansoura University","isPivotal":false,"enrollment":140,"indication":"Mastectomy, Pain, Acute","completionDate":"2028-12-30"},{"nctId":"NCT05852717","phase":"Phase 2","title":"A Phase II Trial Evaluating Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Dipenkumar Modi","isPivotal":false,"enrollment":32,"indication":"Large Cell Lymphoma, Diffuse, Relapsed Cancer","completionDate":"2028-11"},{"nctId":"NCT06979596","phase":"Phase 2","title":"A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors (OMAHA-015)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","isPivotal":false,"enrollment":250,"indication":"Malignant Neoplasm","completionDate":"2027-11-04"},{"nctId":"NCT00111072","phase":"Phase 2","title":"Dexamethasone 0.01% Solution for the Treatment of Oral Lichen Planus","status":"COMPLETED","sponsor":"National Institute of Dental and Craniofacial Research (NIDCR)","isPivotal":false,"enrollment":70,"indication":"Oral Lichen Planus","completionDate":"2006-03"},{"nctId":"NCT00261612","phase":"Phase 2","title":"","status":"UNKNOWN","sponsor":"Medical University of Vienna","isPivotal":false,"enrollment":16,"indication":"Lymphoma, Mantle-Cell","completionDate":"2007-01"},{"nctId":"NCT01969565","phase":"Phase 2","title":"An Open-label, Single-arm, Phase 1b/ 2 Study of Carfilzomib in Combination With Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma","status":"TERMINATED","sponsor":"Emory University","isPivotal":false,"enrollment":1,"indication":"Multiple Myeloma","completionDate":"2014-10"},{"nctId":"NCT04783194","phase":"NA","title":"Dexamethasone Plus Bupivacaine Versus Bupivacaine in Bilateral Trans-incisional Paravertebral Block in Lumbar Spine Surgeries, a Randomized Clinical Trial.","status":"COMPLETED","sponsor":"Ain Shams University","isPivotal":false,"enrollment":50,"indication":"Anesthesia","completionDate":"2022-10-20"},{"nctId":"NCT07513129","phase":"Phase 1","title":"A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And Lymphomas","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":18,"indication":"T-cell Acute Lymphoblastic Leukemia, Lymphoma","completionDate":"2031-12-31"},{"nctId":"NCT01960530","phase":"Phase 1","title":"An Open Label, Partially Randomised, Single Dose, Crossover Study to Evaluate the PK, Oral Bioavailability and Relationship to Metabolic Parameters of Hydrocortisone and Infacort® in Healthy Adult Mal","status":"COMPLETED","sponsor":"Neurocrine UK Limited","isPivotal":false,"enrollment":14,"indication":"Adrenal Insufficiency","completionDate":"2014-11"},{"nctId":"NCT03942601","phase":"Phase 2","title":"Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization","status":"TERMINATED","sponsor":"Mercator MedSystems, Inc.","isPivotal":false,"enrollment":10,"indication":"Peripheral Arterial Disease","completionDate":"2021-04-30"},{"nctId":"NCT06627751","phase":"Phase 2","title":"Phase II Clinical Trial of Mezigdomide/Carfilzomib/Dexamethasone (MeziKD) in Patients With Relapsed or Refractory Multiple Myeloma (MM) With Extramedullary Disease (EMD)","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","isPivotal":false,"enrollment":28,"indication":"Extramedullary Disease in Multiple Myeloma, Recurrent Multiple Myeloma","completionDate":"2030-05-01"},{"nctId":"NCT00097981","phase":"Phase 3","title":"A Randomized, Open-Label, Multi-Center Trial Comparing Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Subjects With Newly Diagnosed Mult","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","isPivotal":true,"enrollment":225,"indication":"Multiple Myeloma","completionDate":"2009-10"},{"nctId":"NCT03605719","phase":"Phase 1","title":"PD1 Blockade and Oncolytic Virus in Relapsed Multiple Myeloma","status":"COMPLETED","sponsor":"Emory University","isPivotal":false,"enrollment":23,"indication":"Recurrent Plasma Cell Myeloma","completionDate":"2022-10-10"},{"nctId":"NCT02666209","phase":"N/A","title":"Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma","status":"NO_LONGER_AVAILABLE","sponsor":"Dana-Farber Cancer Institute","isPivotal":false,"enrollment":0,"indication":"Multiple Myeloma in Relapse, Multiple Myeloma","completionDate":""},{"nctId":"NCT00711555","phase":"Phase 2","title":"An Open Label Phase II Study of Aprepitant for Multi-day Moderately-high to Highly Emetogenic Chemotherapy Regimens","status":"COMPLETED","sponsor":"University of Illinois at Chicago","isPivotal":false,"enrollment":22,"indication":"Nausea, Vomiting","completionDate":"2009-01"},{"nctId":"NCT07068230","phase":"Phase 4","title":"Comparing the Effects of Ondansetron Versus Dexamethasone on the Incidence of Post-dural Puncture Headache (PDPH) , Nausea and Vomiting After Spinal Anaesthesia of Parturients Undergoing Caesarean Sec","status":"COMPLETED","sponsor":"Minia University","isPivotal":false,"enrollment":150,"indication":"Postdural Puncture Headache, Postoperative Nausea and Vomiting","completionDate":"2019-10-01"},{"nctId":"NCT00866307","phase":"Phase 1","title":"Intensified PEG-Asparaginase in High Risk Acute Lymphoblastic Leukemia (ALL): A Pilot Study","status":"COMPLETED","sponsor":"Children's Oncology Group","isPivotal":false,"enrollment":104,"indication":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia","completionDate":"2021-03-31"},{"nctId":"NCT04940338","phase":"Phase 4","title":"The Effect of Topical Corticosteroids and Topical NSAIDs Perioperatively on IL6 Levels in Aqueous Humor and on Incidence of PCME in Patients With NPDR","status":"COMPLETED","sponsor":"Klinički Bolnički Centar Zagreb","isPivotal":false,"enrollment":90,"indication":"Cystoid Macular Edema Following Cataract Surgery","completionDate":"2022-01-01"},{"nctId":"NCT03889444","phase":"N/A","title":"Drug Utilization Study in Patients Receiving Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)","status":"COMPLETED","sponsor":"Allergan","isPivotal":false,"enrollment":141,"indication":"Diabetic Macular Edema","completionDate":"2019-06-07"},{"nctId":"NCT02623426","phase":"Phase 3","title":"Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial","status":"COMPLETED","sponsor":"JHSPH Center for Clinical Trials","isPivotal":true,"enrollment":194,"indication":"Uveitis, Macular Edema","completionDate":"2022-02-02"},{"nctId":"NCT06407544","phase":"NA","title":"Prospective Comparative Study Between Ultrasound-guided Quadratus Lumborum Block Versus Fascia Iliaca Compartment Block for Postoperative Pain and Cognitive Dysfunction Management in Patient Undergoin","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","isPivotal":false,"enrollment":60,"indication":"Pain and Cognitive Dysfunction Management in Hip Surgery","completionDate":"2026-05"},{"nctId":"NCT03326544","phase":"NA","title":"Ultra-sound Guided Saphenous Nerve Block Versus Platelet Rich Plasma for Chronic Knee Joint Osteoarthritis","status":"COMPLETED","sponsor":"Mansoura University","isPivotal":false,"enrollment":56,"indication":"Chronic Knee Joint Osteoarthritis","completionDate":"2018-09-30"},{"nctId":"NCT06131593","phase":"NA","title":"TAP Block With Dexamethasone Versus TAP Block With Methyl-prednisolone as a Pain Treatment Modality After Total Abdominal Hysterectomy Procedures: Randomized Controlled Trial","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","isPivotal":false,"enrollment":50,"indication":"Local Anesthetic, Ultrasound","completionDate":"2024-04-20"},{"nctId":"NCT04270409","phase":"Phase 3","title":"A Phase 3 Randomized, Open-label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smolde","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","isPivotal":true,"enrollment":337,"indication":"Plasma Cell Myeloma","completionDate":"2033-10-21"},{"nctId":"NCT02079649","phase":"Phase 2","title":"A Prospective, Randomized, Double-Masked, Vehicle and Active-Controlled, Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for the Treatment of Allergic Conjunctivitis in an Envi","status":"COMPLETED","sponsor":"Alcon Research","isPivotal":false,"enrollment":224,"indication":"Allergic Conjunctivitis","completionDate":"2014-07"},{"nctId":"NCT02320006","phase":"EARLY/Phase 1","title":"","status":"UNKNOWN","sponsor":"Li Liu","isPivotal":false,"enrollment":120,"indication":"Female Infertility Due to Occlusion of Fallopian Tube","completionDate":""},{"nctId":"NCT02991404","phase":"EARLY/Phase 1","title":"Single Injection Adductor Canal Block Versus Continuous Adductor Canal Infusion for Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","isPivotal":false,"enrollment":60,"indication":"Total Knee Arthroplasty, Pain, Postoperative","completionDate":"2017-11-15"},{"nctId":"NCT00825071","phase":"Phase 4","title":"Optimizing Anesthesia Antiemetic Measures Versus Combination With Dexamethasone or Ondansetron in the Prevention of Postoperative Nausea and Vomiting.","status":"COMPLETED","sponsor":"University of Jordan","isPivotal":false,"enrollment":180,"indication":"Postoperative Nausea and Vomiting","completionDate":"2008-03"},{"nctId":"NCT05393726","phase":"NA","title":"Ultrasound-Guided Suprainguinal Fascia Iliaca Block Versus Lumbar Erector Spinae Plane Block for Oncologic Thigh Surgery: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"National Cancer Institute, Egypt","isPivotal":false,"enrollment":75,"indication":"Perioperative Pain","completionDate":"2024-09-30"},{"nctId":"NCT07425678","phase":"Phase 4","title":"Perioperative Analgesic Management Using Conventional Versus Regional Nerve Block in Craniotomy Surgeries in Lower Middle-Income Class Countries","status":"COMPLETED","sponsor":"Aga Khan University","isPivotal":false,"enrollment":62,"indication":"Supratentorial Tumors","completionDate":"2025-09-30"},{"nctId":"NCT06307444","phase":"NA","title":"Ultrasound-Guided Erectro Spinae Plane Block Versus Stellate Ganglion Block for Patients With Upper Limb Acute Herpes Zoster Pain: Randomized Controlled Study","status":"COMPLETED","sponsor":"Tanta University","isPivotal":false,"enrollment":93,"indication":"Acute Herpes Zoster Pain Managment","completionDate":"2025-02-01"},{"nctId":"NCT03383328","phase":"Phase 4","title":"Effect of Drop-less Surgery Compared to Topical NSAID Alone and Combination of Steroid and NSAID on Central Macular Thickness After Cataract Surgery, a Randomized Controlled Trial","status":"COMPLETED","sponsor":"Line Kessel","isPivotal":false,"enrollment":470,"indication":"Postoperative Cystoid Macular Edema, Irvine-Gass Syndrome","completionDate":"2019-12-18"},{"nctId":"NCT04540133","phase":"Phase 2","title":"Dexamethasone Solution and Dexamethasone in Mucolox™ for the Treatment of Oral Inflammatory Ulcerative Diseases","status":"COMPLETED","sponsor":"University of California, San Francisco","isPivotal":false,"enrollment":29,"indication":"Oral Lichen Planus, Mucous Membrane Pemphigoid","completionDate":"2023-01-06"},{"nctId":"NCT06658418","phase":"Phase 1","title":"Erector Spinae Plane Block with Dexmedetomidine and Bupivacain Versus Dexamethasone and Bupivacain for Postoperative Analgesia in Patients Undergoing Abdominal Surgeries","status":"NOT_YET_RECRUITING","sponsor":"Loay Gamal","isPivotal":false,"enrollment":90,"indication":"Analgesia, Postoperative","completionDate":"2026-12-01"},{"nctId":"NCT02514382","phase":"Phase 1","title":"A Phase 1b Study of REOLYSIN® (Reovirus Serotype 3 - Dearing Strain) Combined With Standard Doses of Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"University of Southern California","isPivotal":false,"enrollment":14,"indication":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","completionDate":"2022-04-19"},{"nctId":"NCT05232825","phase":"Phase 3","title":"A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Scleros","status":"COMPLETED","sponsor":"Hoffmann-La Roche","isPivotal":true,"enrollment":236,"indication":"Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis","completionDate":"2025-06-06"},{"nctId":"NCT00910897","phase":"Phase 3","title":"A Phase 3 Study of Velcade (Bortezomib) Dexamethasone (VD) Versus Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) as an Induction Treatment Prior to Autologous Stem Cell Transplantation in Patien","status":"UNKNOWN","sponsor":"Intergroupe Francophone du Myelome","isPivotal":true,"enrollment":205,"indication":"Multiple Myeloma","completionDate":""},{"nctId":"NCT03220113","phase":"Phase 1","title":"Safety and Efficacy of De-Novo Algorithm and Formula in the Treatment of Patients With Intractable Chronic Craniofacial Neuralgia, or Chronic Migraine Headaches.","status":"UNKNOWN","sponsor":"Corona Doctors Medical Clinics, Inc.","isPivotal":false,"enrollment":100,"indication":"Chronic Migraine Without Aura, Intractable, Migraine With Typical Aura","completionDate":"2019-07-01"},{"nctId":"NCT04065308","phase":"Phase 2","title":"A Phase II Trial to Evaluate the Efficacy of Daratumumab With DCEP in Multiply Myeloma Patients With Plasmacytoma Who Fail to Achieve Complete Remission With Bortezomib Containing Induction Regimen","status":"UNKNOWN","sponsor":"Seoul National University Hospital","isPivotal":false,"enrollment":33,"indication":"Multiple Myeloma in Relapse, Plasmacytoma","completionDate":"2021-09-30"},{"nctId":"NCT02304250","phase":"NA","title":"The Effect of Dexamethasone on Safety of Thyroid Surgery","status":"COMPLETED","sponsor":"Quanhong Zhou","isPivotal":false,"enrollment":220,"indication":"Wound Infection","completionDate":"2015-07"}],"whoEssential":true,"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"Oral","frequency":"Once daily or variable","formulation":"Tablet, Oral solution, Injectable, Eye drops"},"crossReferences":{"unii":"7S5I7G3JQL","rxcui":"3264","splId":"4250a0b0-e539-57c9-e063-6294a90a4b55","chemblId":"CHEMBL1697787","pubchemSID":"92119"},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":72782,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"1958-10-30","companionDiagnostics":[],"firstApprovalCountry":"United States","genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-03-02T00:00:00.000Z","mah":"OCULAR THERAPEUTIX","brand_name_local":null,"application_number":"NDA208742"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-08-16T00:00:00.000Z","mah":"HARROW EYE","brand_name_local":null,"application_number":"NDA050818"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-09-08T00:00:00.000Z","mah":"AMNEAL","brand_name_local":null,"application_number":"ANDA216295"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-04-26T00:00:00.000Z","mah":"BIONPHARMA","brand_name_local":null,"application_number":"ANDA217538"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-06-05T00:00:00.000Z","mah":"HIKMA","brand_name_local":null,"application_number":"ANDA084282"},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":"EMEA/H/C/004071"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Neofordex","application_number":null}],"patentsNormalised":[{"patent_number":"8563027","territory":"US","patent_type":"Method of Use","expiry_date":"2030-02-12T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8409606","territory":"US","patent_type":"Formulation","expiry_date":"2030-05-14T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10799642","territory":"US","patent_type":"Formulation","expiry_date":"2032-05-11T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10028965","territory":"US","patent_type":"Method of Use","expiry_date":"2034-05-23T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10159683","territory":"US","patent_type":"Formulation","expiry_date":"2034-05-23T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10022502","territory":"US","patent_type":"Method of Use","expiry_date":"2034-06-22T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"12150896","territory":"US","patent_type":"Method of Use","expiry_date":"2036-10-07T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11458041","territory":"US","patent_type":"Method of Use","expiry_date":"2037-11-16T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11304961","territory":"US","patent_type":"Formulation","expiry_date":"2037-12-18T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10537585","territory":"US","patent_type":"Formulation","expiry_date":"2037-12-18T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11097061","territory":"US","patent_type":"Formulation","expiry_date":"2039-06-23T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"12144889","territory":"US","patent_type":"Method of Use","expiry_date":"2041-04-26T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"pricingByCountry":[{"country_code":"Un","currency":"USD","price_amount":"2617.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"2617.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"2617.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"2617.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"2617.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":64,"withResults":23},"validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T08:32:54.255024+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}